8-K
Stimcell Energetics Inc. (STME)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 25, 2022
CELL MEDX CORP.
(Exact name of registrant as specified in its charter)
| NV | 000-54500 | 38-3939625 |
|---|---|---|
| (State or other jurisdiction of<br><br><br>incorporation) | (Commission File<br><br><br>Number) | (IRS Employer Identification No.) |
| 123 W. Nye Ln, Suite 446<br><br><br>Carson City , NV | 89706 | |
| (Address of principal executive<br><br><br>offices) | (Zip Code) | |
| Registrant's telephone number, including area code | ( 844 ) 238-2692 |
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
ITEM 5.02****DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On April 25, 2022, the board of directors of Cell MedX Corp. (the “Company”) unanimously resolved to increase the number of directors of the Company to six directors and to appoint Mr. Dwayne Yaretz as a director to fill the vacancy created by the increase in the number of directors. In addition, Mr. Yaretz was appointed Chief Executive Officer of the Company, replacing Mr. McEnulty, who resigned from his position as CEO of the Company on April 25, 2022. Mr. McEnulty will continue to serve on the Company’s board of directors.
Mr. Yaretz’ experience spans many industries including the development of industrial and medical imaging devices. He has aided in the re-structure of numerous companies by identifying and recruiting key personnel, enhancing the management team, capitalization, and maximizing business and sales opportunities. In the past, Mr. Yaretz has acted as a director, and held various top management positions, including CEO, CFO and president, with both private and public companies.
There is no family relationship among the directors. There are currently no compensation arrangements with Mr. Yaretz for acting as a member of the board of directors, or as the CEO.
A copy of the Company’s news release regarding the appointment of Mr. Yaretz and resignation of Mr. McEnulty is attached as Exhibit 99.1 hereto*.*
ITEM 9.01****FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
The following exhibits are provided with this Current Report:
| Exhibit<br><br><br>Number | Description of Exhibit |
|---|---|
| 99.1 | News Release dated April 27, 2022. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CELL MEDX CORP. | |
|---|---|
| Date: April 27, 2022 | |
| By: /s/ Joao (John) da Costa | |
| Joao (John) da Costa, | |
| Chief Operating Officer |
3
CELL MEDX CORP. OTCQB: CMXC
FOR IMMEDIATE RELEASE APRIL 27, 2022
Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director
Carson City, Nevada, April 27, 2022, Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has appointed Mr. Dwayne Yaretz to the Board of Directors and as Chief Executive Officer. Mr. Yaretz replaces Mr. McEnulty, as CEO of the Company. Mr. McEnulty will continue to serve as a director of Cell MedX.
Mr. Yaretz’ experience spans many industries including the development of industrial and medical imaging devices. He has aided in the re-structure of numerous companies by identifying and recruiting key personnel, enhancing the management team, capitalization, and maximizing business and sales opportunities.
Mr. Yaretz has acted as a Director, President and CEO, Corporate Secretary and CFO for both private and public companies.
Mr. Yaretz commented, “I am excited to join the Cell MedX team, to prepare the Company to capitalize on its current Health Canada approvals for its eBalance® Systems, and in preparation of FDA 510K clearance to enter the US Market. It is my hope that Cell MedX will provide its rigorously tested microcurrent technology solution to millions of people who suffer from pain and would benefit from a safe, easy-to-use, non-invasive solution.”
Mr. McEnulty, Director and former CEO of the Company, stated, “We are very excited to welcome Mr. Yaretz to the Cell MedX team. His wealth of experience in the capital markets along with his manufacturing and medical devices background is a great asset to the Company.”
About Cell MedX Corp. (OTCQB: CMXC)
Cell MedX Corp. is a biotech company focused on the continued research and development of its eBalance® Technology and its eBalance® Home and eBalance® Pro Systems, which have received Health Canada Approval as Class II Medical Device Systems for pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities and lower extremities due to strain from exercise or normal household- or work-related activities, as well as for general relaxation. In addition, the Company will work towards the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson’s disease, high blood pressure, neuropathy and kidney function. For more information about the Company and its technology please visit www.cellmedx.com
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Director
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
SOURCE:
Cell MedX Corp.
For further information visit: www.cellmedx.com.
Investor Relations: 1-844-238-2692